REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2012

Dec 3, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2012-11-29

Reporting Person: Aberman Michael S (VP Strategy and Investor Relat)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-11-29	Common Stock	M	8334.0	$24.0	Acquired	18834.0	Direct
2012-11-29	Common Stock	F	1097.0	$182.2	Disposed	17737.0	Direct
2012-11-29	Common Stock	F	3333.0	$182.2	Disposed	14404.0	Direct
2012-11-30	Common Stock	S	3004.0	$180.08	Disposed	11400.0	Direct
2012-11-30	Common Stock	S	400.0	$181.59	Disposed	11000.0	Direct
2012-11-30	Common Stock	S	200.0	$182.39	Disposed	10800.0	Direct
2012-11-30	Common Stock	S	200.0	$183.77	Disposed	10600.0	Direct
2012-11-30	Common Stock	S	100.0	$184.0	Disposed	10500.0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-11-29	Non-Qualified Stock Option (right to buy)	$24.0	M	8334.0	Disposed	2020-03-22	Common Stock (8334.0)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	287.0	Indirect

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: Represents volume-weighted average price of sales of 3,004 shares of Company stock on November 30, 2012 at prices ranging from $180.00 to $180.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 30, 2012 at each separate price.

F3: Represents volume-weighted average price of sales of 400 shares of Company stock on November 30, 2012 at prices ranging from $181.29 to $181.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 30, 2012 at each separate price.

F4: Represents volume-weighted average price of sales of 200 shares of Company stock on November 30, 2012 at prices ranging from $182.38 to $182.40. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 30, 2012 at each separate price.

F5: Represents volume-weighted average price of sales of 200 shares of Company stock on November 30, 2012 at prices ranging from $183.64 to $183.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 30, 2012 at each separate price.

F6: The stock option award (combined incentive stock option and non-qualified stock option) vests over five years, commencing one year after the date of grant. 12,500 options vest on the first anniversary, 25,000 options vest on the second anniversary, 25,000 options vest on the third anniversary, 25,000 options vest on the fourth anniversary, and 12,500 options vest on the fifth anniversary of the date of grant.

F7: Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.